Korea's Ministry of Food and Drug Safety has expanded the label for Prevymis, an antiviral known generically as letermovir, to include pediatric use for preventing cytomegalovirus (CMV) infection and disease, MSD Korea said Tuesday. (Korea Biomedical Review) - Oct 14, 2025 - "The decision was issued on Sept. 29....The decision is supported by P030, a phase 2b, open-label, single-arm study in patients 18 years or younger at risk for CMV after allogeneic stem-cell transplant."
Korea approval • Cytomegalovirus Infection
|